$1.07
+0.02 (+1.90%)
Open$1.03
Previous Close$1.05
Day High$1.10
Day Low$0.98
52W High$9.90
52W Low$1.46
Volume—
Avg Volume393.1K
Market Cap5.71M
P/E Ratio—
EPS$-4.88
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+3,537.4% upside
Current
$1.07
$1.07
Target
$38.92
$38.92
$24.59
$38.92 avg
$51.00
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 555.8K | 518.1K | 501.1K |
| Net Income | 113.5K | 116.0K | 100.3K |
| Profit Margin | 20.4% | 22.4% | 20.0% |
| EBITDA | 245.4K | 221.0K | 210.9K |
| Free Cash Flow | 70.8K | 77.8K | 93.1K |
| Rev Growth | -5.3% | +6.0% | -5.8% |
| Debt/Equity | 0.43 | 0.40 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |